Contract Services
PCI Pharma Services to acquire Sherpa Clinical Packaging 12th September 2018
PCI Pharma Services has entered an agreement to acquire Sherpa Clinical Packaging, a provider of clinical trial material management services for clinical studies, including packaging, labeling, distribution, storage and returns and destruction services. Sherpa’s facilities employ cold chain technologies that include handling products requiring labeling and kitting at frozen and refrigerated conditions.
“Sherpa has always been committed to providing our customers with the best customer service and expertise in clinical supply management,” said Mark Paiz, president of Sherpa. “With this acquisition, our customers will now have access to PCI’s expanded clinical packaging services, extensive manufacturing of clinical trial materials, as well as global reach through U.S., European, and Asia Pacific depots to support their clinical studies.”
PCI provides global molecule-to-market services that span contract development and manufacturing, including specialization in highly complex and potent drugs, clinical supply services and commercial packaging services. PCI’s clinical services include drug development and manufacturing, packaging and labeling, storage and logistical services, including support for Cold Chain and Ultra Cold Chain down to -196°C. The company is strategically investing in the expansion of its global Clinical Services business and this marks its third acquisition in 12 months.
“We are extremely excited for what Sherpa brings to the PCI business,” said Salim Haffar, chief executive officer of PCI. “We have experienced considerable growth in our clinical business, and over the past 12 months made a number of key acquisitions to further expand our presence in key geographies including Ireland, Australia, and now California, along the way adding exciting new capabilities. Our #1 commitment to our clients is to provide the industry leading experience. This includes outstanding service, expansive capability, as well as the ability to support client studies around the world. Sherpa’s tremendous growth and reputation is clearly founded in their dedication to servicing their customers at the highest levels, which very much aligns to our core mission.”
“Sherpa has always been committed to providing our customers with the best customer service and expertise in clinical supply management,” said Mark Paiz, president of Sherpa. “With this acquisition, our customers will now have access to PCI’s expanded clinical packaging services, extensive manufacturing of clinical trial materials, as well as global reach through U.S., European, and Asia Pacific depots to support their clinical studies.”
PCI provides global molecule-to-market services that span contract development and manufacturing, including specialization in highly complex and potent drugs, clinical supply services and commercial packaging services. PCI’s clinical services include drug development and manufacturing, packaging and labeling, storage and logistical services, including support for Cold Chain and Ultra Cold Chain down to -196°C. The company is strategically investing in the expansion of its global Clinical Services business and this marks its third acquisition in 12 months.
“We are extremely excited for what Sherpa brings to the PCI business,” said Salim Haffar, chief executive officer of PCI. “We have experienced considerable growth in our clinical business, and over the past 12 months made a number of key acquisitions to further expand our presence in key geographies including Ireland, Australia, and now California, along the way adding exciting new capabilities. Our #1 commitment to our clients is to provide the industry leading experience. This includes outstanding service, expansive capability, as well as the ability to support client studies around the world. Sherpa’s tremendous growth and reputation is clearly founded in their dedication to servicing their customers at the highest levels, which very much aligns to our core mission.”
